No trial has tested this combination in people. Each compound below has whatever evidence it has, on its own. Putting two or three of them in one vial does not combine their evidence, and no study has looked at what they do together, in what order, or at what cost. Everything on this page about the pairing is a description of what is claimed for it, not a finding.
What is in it
Two different molecules are sold under one name, and the difference is not a detail. CJC-1295 with DAC — ConjuChem's actual clinical compound — binds covalently to albumin and acts for days.…
- Evidence
- Limited
- Status
- Research Use Only
- Documented risks
- 10 · 5 serious
The most selective of the growth hormone-releasing peptides — it triggers GH release with minimal effect on cortisol, prolactin or appetite. That selectivity is real and is why it displaced …
- Evidence
- Limited
- Status
- Research Use Only
- Documented risks
- 9 · 3 serious
Why it is sold this way
The pairing is justified on mechanism. The two components act at different receptors on the same pathway — one mimics growth-hormone-releasing hormone, the other mimics ghrelin at the growth hormone secretagogue receptor — and the combination is described as synergistic rather than merely additive. The "without DAC" qualifier matters and is frequently lost in the marketing: the drug affinity complex version has a far longer duration of action and a different pulse profile, and the two are not interchangeable.
What the combination actually has behind it
Both components raise growth hormone; that much is not seriously disputed and is measurable. What has never been established in a human trial is that the combination changes any outcome a person would notice — body composition, strength, recovery or injury risk — or that raising growth hormone in a healthy adult is beneficial at all. The evidence ratings on the two monographs below are both low, and combining two compounds rated that way does not produce a compound rated higher.
| CJC-1295 |
2/5 Limited
Evidence rating 2 out of 5: Limited
Preclinical work plus scattered human reports, uncontrolled use, or negative trials. |
|---|---|
| Ipamorelin |
2/5 Limited
Evidence rating 2 out of 5: Limited
Preclinical work plus scattered human reports, uncontrolled use, or negative trials. |
| The blend | No human trial of the combination exists. The figure that matters for a mixture is its weakest component, which here is 2 of 5. |
What mixing them makes impossible
A fixed ratio in one vial removes the ability to change one thing at a time. If it helps, it is not possible to say which component did it; if something goes wrong — water retention, numb hands, a rising fasting glucose, a reaction at the injection site — it is not possible to say which component caused it, or to stop one and keep the other. Neither is it possible to confirm that a vial labelled as two compounds contains either of them, let alone both in the stated proportion.
Change one thing at a time. This is the most useful rule on the safety page and a fixed mixture breaks it by design. If a blend helps, you cannot say which part helped; if it harms, you cannot say which part harmed, or stop that part alone.
Regulatory status
Neither component is an approved medicine in the United States, and the compounding position of each is tracked separately in the dated record below.
| CJC-1295 | Category 2 — compounding not permitted Still in Category 2 of the 503A review, so not eligible for lawful pharmacy compounding in the United States. This compound is also the subject of the continuing litigation the record describes. |
|---|---|
| Ipamorelin | Category 2 — compounding not permitted Still in Category 2 of the 503A review, so not eligible for lawful pharmacy compounding in the United States. This compound is also the subject of the continuing litigation the record describes. |
The dated record for the compounds this site tracks is on the compounding status page, which is checked against the FDA's own documents rather than against anybody's description of them. A committee recommendation is not FDA action, removal from a list is not permission, and none of it is drug approval.
Related compounds
This page is educational information, not medical advice. It cannot account for your medical history, medications or risk factors. Do not start, stop or change any treatment based on it.